Haemophilus influenza type B vaccine - Development Center for Biotechnology/Unknown
Alternative Names: LT-Hib vaccineLatest Information Update: 18 Jan 2024
At a glance
- Originator Development Center for Biotechnology
- Developer Development Center for Biotechnology; Unknown
- Class Haemophilus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Haemophilus infections
Most Recent Events
- 18 Jan 2024 Haemophilus influenza type B vaccine is still in phase I trials for Haemophilus infections in the US (Parenteral) (Development Center for Biotechnology, pipeline, January 2024)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Haemophilus-infections(Prevention) in USA (Parenteral)
- 30 Nov 2020 Development Center for Biotechnology out-licenses the Haemophilus influenza type B vaccine, before November 2020 (Development Center for Biotechnology pipeline, November 2020)